Oral Abstract Session:
115. HIV-Related Comorbidities and Complications
Friday, October 5, 2018: 8:45 AM-10:00 AM
Room: S 157

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID

Moderators:  Priscilla Hsue, MD, UCSF School of Medicine and Heidi M. Crane, MD, MPH, University of Washington

8:45 AM
Serum Albumin is Associated with Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection
Sahera Dirajlal-Fargo, M.S, D.O., FAAP; Manjusha Kulkarni, PhD; Abdus Sattar, PhD; Nicholas Funderburg, PhD; Grace A McComsey, MD
9:00 AM
Incidence of Skin and Soft Tissue Infection in People Living with HIV in a Large Urban Public Health Care System in Houston, Texas, 2009-2014
Vagish Hemmige, MD; Cesar Arias, MD, PhD, FIDSA; Siavash Pasalar, PhD; Thomas P. Giordano, M.D., M.P.H., FIDSA
9:15 AM
Repeat Pregnancies Among Women Living with HIV: Evaluating temporal changes in HIV disease status and exploring the association between preterm birth and protease inhibitor use in pregnancy.
Brigid O'Brien, DO, MS; Paige Williams, PhD; Deborah Kacanek, ScD; Ellen Chadwick, MD; Kathleen Powis, MD, MPH; Katharine Correia, MA, Biostatistics; Lisa B. Haddad, MD, MS, MPH; Lynn Yee, MD, MPH; Nahida Chakhtoura, MD; Chi Dola, MD, MPH; Russell B. Van Dyke, MD
9:30 AM
Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
Philip Lackey, MD; Laurence Brunet, PhD; Jennifer Fusco, BS; Vani Vannappagari, MBBS, MPH, PhD; Leigh Ragone, MS; Gregory Fusco, MD, MPH
9:45 AM
Virally Suppressed PLH switching from Abacavir to Tenofovir Alafenamide did not have changes in immune activation or inflammation.
Nicholas Funderburg, PhD; Grace Mccomsey, MD, FIDSA; Manjusha Kulkarni, PhD; Emily R. Bowman, PhD; Janelle Gabriel, PhD; Brandon Snyder, BS; Patrick Mallon, MD, PhD; Alan Winston, MD, PhD; Devi Sengupta, MD; Mingjin Yan, PhD; Martin S Rhee, MD; Moupali Das, MD, MPH

CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.